Bolstered by the latest preclinical data, Psilera is poised to
advance their lead asset, PSIL-006, towards first-in-human studies
for Frontotemporal Dementia (FTD).
TAMPA,
Fla., Aug. 27, 2024 /PRNewswire/ -- Psilera,
Inc. (Psilera), a leading biotechnology company developing
therapies for rare neurological disorders, has received initial
toxicity readouts from maximum tolerated dose (MTD) in vivo
studies showing a strong safety profile. Additional preclinical
in vivo efficacy studies, conducted through the University of South Florida, have shown PSIL-006's
ability to improve the sleep, learning, and memory in humanized Tau
mouse models.
PSIL-006 preclinical data promising for
FTD
"From the start, our primary focus was to develop a new class of
neurological therapies for patients that eliminate unnecessary
side-effects which traditionally limited patient access to natural
compounds with high therapeutic potential," said Psilera Co-Founder
and Chief Scientific Officer Dr. Jackie von
Salm. "This initial data reinforces our strong belief that
neuroplastogens have tremendous untapped potential."
Elizabeth Finger, M.D., Psilera's
clinical advisor and the leading expert of FTD research and
therapeutics, provides guidance to the PSIL-006 development program
to ensure patient safety is prioritized. The entire team believes
strongly that PSIL-006 has the potential to improve the quality of
life of patients and caregivers for this devastating disease.
The Psilera Third Eye™ platform uses optimized natural
compounds that mimic the body's naturally produced serotonin to
design therapeutics like PSIL-006 to effectively deliver medicine
directly to targeted brain receptors. Psilera intends to
demonstrate the potential of its non-hallucinogenic neuroplastogens
in traditional double-blind, placebo controlled trials without in
clinic dosing, providing a better care model for patients and
physicians.
About Psilera:
Psilera is a biopharmaceutical company focused on developing
groundbreaking therapeutics for neurodegenerative diseases by
creating a new class of neurological medicines. Psilera's lead
asset, PSIL-006, is a non-hallucinogenic psilocybin derivative for
the treatment of frontotemporal dementia (FTD). With a deep
commitment to improving the patient experience through scientific
excellence, Psilera is transforming the lives of individuals
affected by devastating diseases. Welcome to the new era of mindful
medicine. For more information visit www.psilera.com.
Investor Contact: Chris
Witowski
Chris@psilera.com
Media Contact: Katie DeMarsh
Katie@psilera.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/psilera-receives-positive-preclinical-in-vivo-data-for-frontotemporal-dementia-ftd-candidate-psil-006-302231547.html
SOURCE Psilera, Inc.